pioglitazone has been researched along with Metabolic Diseases in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Meanwhile, WY-14643 and pioglitazone, 2 drugs widely used for treating metabolic diseases, were employed to prevent oleate-induced disorders of macrophage phospholipid metabolism." | 4.02 | Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages. ( Ai, XY; Chen, J; Gao, H; Huang, Q; Wu, Z; Yang, BC; Ye, G, 2021) |
| "Pioglitazone did not increase weight or produce any other significant side-effects." | 2.78 | Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013) |
| "Pioglitazone treatment of KK-A(y) mice for 14 days significantly reduced the accumulation of inflammatory cells in ischemic myocardium, and infarct size 3 days after reperfusion compared to vehicle treatment (p<0." | 1.35 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. ( Fuchigami, S; Hayasaki, T; Honda, T; Kaikita, K; Matsukawa, M; Ogawa, H; Sakashita, N; Sugiyama, S; Takeya, M; Tsujita, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Colca, JR | 1 |
| Scherer, PE | 1 |
| Ye, G | 1 |
| Yang, BC | 1 |
| Gao, H | 1 |
| Wu, Z | 1 |
| Chen, J | 1 |
| Ai, XY | 1 |
| Huang, Q | 1 |
| Póvoa, VMO | 1 |
| Delafiori, J | 1 |
| Dias-Audibert, FL | 1 |
| de Oliveira, AN | 1 |
| Lopes, ABP | 1 |
| de Paula, EV | 1 |
| Pagnano, KBB | 1 |
| Catharino, RR | 1 |
| Lian, QX | 1 |
| Deng, HZ | 1 |
| Chen, KY | 1 |
| Deng, H | 1 |
| Foryst-Ludwig, A | 1 |
| Clemenz, M | 1 |
| Hohmann, S | 1 |
| Hartge, M | 1 |
| Sprang, C | 1 |
| Frost, N | 1 |
| Krikov, M | 1 |
| Bhanot, S | 1 |
| Barros, R | 1 |
| Morani, A | 1 |
| Gustafsson, JA | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Finsterer, J | 1 |
| Stöllberger, C | 1 |
| Smith, RC | 1 |
| Jin, H | 1 |
| Li, C | 1 |
| Bark, N | 1 |
| Shekhar, A | 1 |
| Dwivedi, S | 1 |
| Mortiere, C | 1 |
| Lohr, J | 1 |
| Hu, Q | 1 |
| Davis, JM | 1 |
| Honda, T | 1 |
| Kaikita, K | 1 |
| Tsujita, K | 1 |
| Hayasaki, T | 1 |
| Matsukawa, M | 1 |
| Fuchigami, S | 1 |
| Sugiyama, S | 1 |
| Sakashita, N | 1 |
| Ogawa, H | 1 |
| Takeya, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894] | Phase 4 | 56 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -6.82 |
| Placebo | -40.72 |
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -24.19 |
| Placebo | 15.19 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -13.33 |
| Placebo | -11.5 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.02 |
| Placebo | 24.20 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.52 |
| Placebo | 7.72 |
serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Piogltiazone | 4.62 |
| Placebo | -2.59 |
(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -49.65 |
| Placebo | 30.99 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 32.56 |
| Placebo | -79.12 |
The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment
| Intervention | Units on RBANS scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | -1.11 |
1 review available for pioglitazone and Metabolic Diseases
| Article | Year |
|---|---|
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
2 trials available for pioglitazone and Metabolic Diseases
| Article | Year |
|---|---|
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up St | 2021 |
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu | 2013 |
5 other studies available for pioglitazone and Metabolic Diseases
| Article | Year |
|---|---|
Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages.
Topics: Animals; Chromatography, Liquid; Lipid Metabolism; Macrophages; Mass Spectrometry; Metabolic Disease | 2021 |
Role of Peroxisome Proliferator-Activated Receptor (PPARγ) in Metabolic Disorders in SGA with Catch-Up Growth.
Topics: Adult; Animals; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Male; Metabolic | 2018 |
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.
Topics: Adipocytes; Animals; Cell Differentiation; Estrogen Receptor beta; Female; Gene Expression; Glucose; | 2008 |
Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.
Topics: Cardiomyopathy, Restrictive; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; | 2009 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.
Topics: Animals; Body Weight; Cells, Cultured; Gene Expression Regulation; Heart Ventricles; Inflammation; M | 2008 |